Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients
- 10 June 2014
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 44 (2) , 145-151
- https://doi.org/10.1016/j.ijantimicag.2014.04.018
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infectionJournal of Hepatology, 2014
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialThe Lancet Infectious Diseases, 2013
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis CNew England Journal of Medicine, 2013
- Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of careThe Lancet Infectious Diseases, 2012
- Review and management of drug interactions with boceprevir and telaprevirHepatology, 2012
- Treatment failure with new hepatitis C drugsExpert Opinion on Pharmacotherapy, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CNature Reviews Gastroenterology & Hepatology, 2011
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis CAnnals of Internal Medicine, 2002